Back to UBS Group AG UBS Group AG

NBIXNBIX
Showing 8 of 29 quarters

Position history for UBS Group AGUBS Group AG's holdings in NEUROCRINE BIOSCIENCES INC

UBS Group AG holds 1.2M shares of NBIX (NEUROCRINE BIOSCIENCES INC), worth $160.9M as of 2026-Q1. The position was increased (+24.1% shares). NBIX represents 0.0% of UBS Group AG's portfolio.

Current Value

$160.9M

Current Shares

1.2M

Total Value Change

+$117.2M

Total Shares Change

+904,109

Quarter-by-Quarter History
QuarterActionSharesChangeValueWeightPriceConviction
2026-Q1
Latest
Increased
1.2M
+24.1%
$160.9M0.0%$131.14
37
2025-Q4
Increased
983,528
+169.8%
$139.5M0.0%$140.95
49
2025-Q3
Decreased
364,572
-39.5%
$51.2M0.0%$140.27
0
2025-Q2
Decreased
602,125
-23.4%
$75.7M0.0%$125.42
0
2025-Q1
Increased
785,501
+87.3%
$86.9M0.0%$113.16
47
2024-Q4
Increased
419,428
+16.6%
$57.3M0.0%$137.06
34
2024-Q3
Increased
359,569
+13.4%
$41.4M0.0%$115.06
33
2024-Q2
Increased
316,927
+34.5%
$43.6M0.0%$137.67
38

Other major holders of NBIX: BlackRock, Inc., BlackRock Finance, Inc.

Analytics tracking helps us improve the product. Essential functions stay on either way. How analytics data is used